Reportlinker Adds The Future of Nutrigenomics: New opportunities in personalized nutrition and food-pharma collaboration

Wednesday, February 17, 2010 Press Release
Email Print This Page Comment

NEW YORK, Feb. 16 announces that a new market research report is available in its catalogue:

The Future of Nutrigenomics: New opportunities in personalized nutrition and food-pharma collaboration

Nutrigenomics explores how nutrients or bioactive dietary compounds can influence gene expression and an individuals risk to certain diseases. Nutrigenetics is the study of how variations in an individual's genetic makeup can increase or decrease the need for a specific nutrient or bioactive food component. Nutrigenomics has the potential to impact various parts of the food chain including the genetic modification of crops and animal feeds, the development of nutrigenomic tests to monitor food safety and personalization of diets, as well as the identification of nutritional supplements and nutrigenomic based products which may offer potential health benefits. The consumer environment is driving growth in the Nutrition & Health market. Over the past decade, consumers have become more concerned for their health and are increasingly inclined to invest in DTC nutrigenetic tests to assess their risk of disease and obtain dietary advice. Healthcare providers too, are keen to shift some of the burden of healthcare costs to individuals and recognize that the personalization of nutrition may be beneficial. The Health and nutrition market is currently worth around $485 billion. This report reviews the business strategies of leading companies regarding the adoption of nutrigenomic technologies and establishment of public-private partnerships as well as potential opportunities for biomarker discovery with the pharma and diagnostic industry to personalize nutrition and medicine.

Table of Contents

The Future of Nutrigenomics

Executive summary 10

Defining nutrigenomics 10

Market drivers 11

Collaborative nutrigenomic research & consortia 12

Leading food & drinks companies: nutrigenomic strategies 13

Leading nutrigenomic testing companies 14

Opportunities: convergence of pharma & diagnostics 15

Challenges: regulation, ethical & IP issues 16

Conclusions 17

Chapter 1 Defining nutrigenomics 20

Summary 20

Introduction 21

'Omic technologies 23

Nutrigenomics and the food & drinks industry 26

Nutrigenomics & food products 28

Nutrigenomics & personalized nutrition 28

Report outline 29

Chapter 2 Market drivers 32

Summary 32

Introduction 33

Drivers for personalized nutrition 34

Healthy aging 34

Consumer demographics 36

Chronic non-communicable disease 38

Urbanization and the emerging markets 40

Global health economics 41

Conclusions on drivers for personalized nutrition 42

Chapter 3 Collaborative nutrigenomic research & consortia 46

Summary 46

Introduction 47

Nutrigenomic research consortia 47

Nutrigenomic research in the EU 49

The European Nutrigenomics Organization (NuGO) 49

DiOGenes 51

TI Food and Nutrition 51

Vision EpiFood Project 53

Canada Foundation for Innovation (CFI) 53

Public-private in age-related diseases 53

Nutrigenomic research in the US 55

Public-private partnership: genetically modified crops 57

Nutrigenomic research across the world 58

International Society of Nutrigenetics/Nutrigenomics (ISNN) 58

Conclusions 59

Chapter 4 Leading food & drinks companies: nutrigenomic strategies 62

Summary 62

Introduction 63

Ingredients manufacturers approach to nutrigenomics 64


Chr Hansen 66

DSM 69

Food manufacturers' approach to nutrigenomics 73

Group Danone 73

Nestlé 76

Unilever 78

Pharma industry M&A in consumer nutrition 80

The evolving open network model 82

Co-development opportunities 86

Areas for market growth & time scales 88

Conclusions 90

Chapter 5 Leading nutrigenomic testing companies 94

Summary 94

Introduction 95

Market leaders 95 97

GeneLink 98

Gene Smart 98

Genova Diagnostics 99

Interleukin Genetics Inc 100

WellGen Inc. 102

Conclusions 104

Chapter 6 Opportunities: convergence of pharma & diagnostics 108

Summary 108

Introduction 109

Nutrigenomics vs pharmacogenomics 110

Global health issues treatment vs prevention 115

Convergence of the pharmaceutical & diagnostic market 116

Conclusions 118

Chapter 7 Challenges: regulation, ethical & IP issues 120

Summary 120

Introduction 121

Regulation of nutrigenomic foods 122

Europe 123

Japan 124

Regulation of nutrigenomic tests 125

Ethical issues 127

Public awareness & perceptions 128

Intellectual Property 129

Conclusions 131

Chapter 8 Conclusions 134

Summary 134

The food & drinks market 135

Global genetic testing market 136

Market trends 136

Overall conclusions 137

Appendix 140

Primary research methodology 140

Acknowledgments 141

Glossary 142

Index 145

Bibliography 148

Endnotes 151

List of Figures

Figure 1.1: Nutrigenetics and nutrigenomics 22

Figure 1.2: The 'omics technologies 24

Figure 1.3: The functional genomic tool box 26

Figure 1.4: Applications of nutrigenomics in the food chain 27

Figure 2.5: Drivers for the food & drinks industry 33

Figure 2.6: The ageing population a driver for personalized nutrition 35

Figure 2.7: Personalized nutrition targeting consumer segments 36

Figure 2.8: Population over 60: world and developed regions (1950-2050) 37

Figure 2.9: Nutritional challenges - obesity & metabolic syndrome 38

Figure 2.10: Growth in consumers in developing & emerging countries (2008-2018) 40

Figure 2.11: Healthcare expenditure as a share of GDP (2006) 41

Figure 2.12: Target population of nutrigenomic based products 43

Figure 4.13: BASF approach to gene discovery 65

Figure 4.14: DSMs sales growth targeting four emerging business areas 70

Figure 4.15 DSMs R&D competencies 72

Figure 4.16 An International and interdisciplinary network 75

Figure 4.17 Diversify & de-risk through externalization 84

Figure 4.18 Open network model 85

Figure 4.19: Waves of nutrigenomic development 90

Figure 5.20: WellGen's nutrigenomic based discovery 103

Figure 6.21: Nutrigenomics vs pharmacogenomics 111

Figure 6.22: Relationship of drugs, disease, genes and gene products 113

Figure 8.23: Health and nutrition market segments (2009) 135

Figure 8.24: Nutrigenomic impact on personalized nutrition 139

List of Tables

Table 3.1: European Consortia and Nutrigenomic Research Programs 50

Table 3.2: Nutrigenomics Network Programs 55

Table 4.3: Stakeholders in nutrigenomic research and personalized nutrition 63

Table 4.4: Chr Hansen - strategic alliances & investments 67

Table 4.5: Nestlé nutrigenomic alliances & investments 77

Table 4.6: Divestment of Animal, Consumer & Medical Nutrition Divisions 80

Table 4.7: Consumer Health Divisions of Pharmaceutical Companies 81

Table 4.8: Alliance between Food, Pharma, Biotech and the Diagnostic Industries 82

Table 5.9: Categorization of genetic variations that may be included in nutrigenomic tests 96

Table 5.10: Categorization of genetic variations that may be included in nutrigenomic tests 97

Table 6.11: Known diet- gene interactions 112

Table 6.12: Known gene-nutrient interactions 114

To order this report:

Genomics Industry: The Future of Nutrigenomics: New opportunities in personalized nutrition and food-pharma collaboration

More Market Research Report

Check our Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg



US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store